EUVIMEDEUVIMED entdecken
Crossref

Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials

Hiroshi Nakase, Baili Chen, Qian Cao, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Dong Il Park, Keira Herr, Bryan Wahking, Wai Chun Yiu, Jianmin Zhuo, Minhu Chen

Intestinal Research · 21.05.2026

DOI: 10.5217/ir.2025.00150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 21.05.2026. Verfasst von Hiroshi Nakase und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AsiaClinical trialCrohn diseaseGuselkumab

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
  • Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Zitieren

APA

Nakase, H., Chen, B., Cao, Q., Matsuoka, K., Hisamatsu, T., Park, D. I., Herr, K., Wahking, B., Yiu, W. C., Zhuo, J., & Chen, M. (2026). Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials. Intestinal Research. https://doi.org/10.5217/ir.2025.00150

Vancouver

Nakase H, Chen B, Cao Q, Matsuoka K, Hisamatsu T, Park DI, et al. Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials. Intestinal Research. 2026. doi:10.5217/ir.2025.00150

BibTeX
@article{Nakase2026,
  author = {Nakase, Hiroshi and Chen, Baili and Cao, Qian and Matsuoka, Katsuyoshi and Hisamatsu, Tadakazu and Park, Dong Il and Herr, Keira and Wahking, Bryan and Yiu, Wai Chun and Zhuo, Jianmin and Chen, Minhu},
  title = {Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials},
  journal = {Intestinal Research},
  year = {2026},
  doi = {10.5217/ir.2025.00150}
}
Kostenlos starten →